Table 1.

Baseline characteristics of patients

Characteristics	Number of patients (n = 216)
Gender, M/F (%male)	123/93 (56.9)
Age (yrs) (mean ± SD) *	53.6 ± 9.0
Initial Weight (Kg) (mean ± SD)*	76.4 ± 14.0
BMI (Kg/m2) (mean ± SD)*	27.5 ± 4.7
Median Aminotrasferase levels. U/L (range)**
Baseline Alanine aminotrasferase (ALT)	95 (61–165)
Baseline Aspartate aminotransferase (AST)	84.5 (52–123)
HCV Genotype, n (%)	n = 216
Genotype 2	12 (5.6)
Genotype 3	204 (94.4)
Response to previous treatment, n (%)	n = 216
Non-responders	128 (59.3)
Relapsers	88 (40.7)
Histological diagnosis, n (%)***	n = 196
Fibrosis stage 0 – 2	47 (24.0)
Fibrosis stage 3 – 4	149 (76.0)
Baseline serum HCV RNA (IU/mL), n (%)****	n = 155
< 800.000	55 (35.5)
≥ 800.000	100 (64.5)

*Mean ± standard deviation.

**Median (range percentile 25 – 75).

***Twenty missing (9.3%).

****Sixty-one missing (28.2%).